(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -8.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.23%.
Biontech Se's revenue in 2026 is $3,011,363,636.On average, 24 Wall Street analysts forecast BNTX's revenue for 2026 to be $468,088,767,111, with the lowest BNTX revenue forecast at $409,672,502,820, and the highest BNTX revenue forecast at $580,622,263,256. On average, 23 Wall Street analysts forecast BNTX's revenue for 2027 to be $474,916,642,158, with the lowest BNTX revenue forecast at $286,517,867,713, and the highest BNTX revenue forecast at $648,901,013,726.
In 2028, BNTX is forecast to generate $608,945,300,488 in revenue, with the lowest revenue forecast at $272,609,233,358 and the highest revenue forecast at $792,792,158,235.